The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making
Open accessAbstract
Purpose: The aim of this study was to evaluate the prognostic value of the WHO proposal, to assess the role of the main prognostic factors in myelodysplastic syndromes (MDSs) classified into WHO subgroups, and to estimate mortality (standardized mortality ratio [SMR]) and life expectancy in these groups as a basis for clinical decision making. Patients and Methods: Four hundred sixty-seven patients who were diagnosed as having de novo MDS at the Division of Hematology, University of Pavia (Pavia, Italy), between 1992 and 2002, were evaluated retrospectively for clinical and hematologic features at diagnosis, overall survival (OS), and progression to leukemia (leukemia-free survival). Results: Significant differences in survival were noted between patients with refractory anemia (RA), refractory cytopenia with multilineage dysplasia, RA with excess blasts, type 1 (RAEB-1), and RAEB-2. The effect of demographic factors on OS was observed in MDS patients without excess blasts (age, P = .001; sex, P = .006), as in the general population. The mortality of RA patients 70 years or older did not differ significantly from that of the general population (SMR, 1.62; P = .06). Cytogenetics was the only International Prognostic Scoring System variable showing a prognostic value in MDS classified into WHO subgroups. Transfusion-dependent patients had a significantly shorter survival than patients who did not require transfusions (P < .001). Developing a secondary iron overload significantly affected the survival of transfusion-dependent patients (P = .003). Conclusion: These data show that the WHO classification of MDSs has a relevant prognostic value. This classification, along with cytogenetics, might be useful in decisions regarding transplantation. MDS with isolated erythroid lineage dysplasia identifies a subset of truly low-risk patients, for whom a conservative approach is advisable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
Myelodysplastic syndromes: a scoring system with prognostic significance
Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507
Sanz, G., Sanz, M., Vallespi, T., Canizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & San Miguel, J. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406
Myelodysplastic Syndromes — Coping with Ineffective Hematopoiesis
Cazzola, M., & Malcovati, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048266 · Cited by 343
Self-citationMorel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes
Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D., Parker, J., & of the UK MDS Guidelines Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.03907.x · Cited by 298
Germing, U., Gattermann, N., Strupp, C., Aivado, M., & Aul, C. (2000) · Leukemia Research · doi:10.1016/s0145-2126(00)00088-6 · Cited by 296
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.
Sierra, J., Pérez, W. S., Rozmán, C., Carreras, E., Klein, J. P., Rizzo, J. D., Davies, S. M., Lazarus, H. M., Bredeson, C., Marks, D. I., et al. (2002) · PubMed · Cited by 291
Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265
De Witte, T., Hermans, J., Vossen, J., Bacigalupo, A., Meloni, G., Jacobsen, N., Ruutu, T., Ljungman, P., Gratwohl, A., Runde, V., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02200.x · Cited by 251
Boultwood, J., Lewis, S., & Wainscoat, J. (1994) · Blood · doi:10.1182/blood.v84.10.3253.3253 · Cited by 246
Alessandrino, E. P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L. N., Locatelli, F., Marchetti, M., Morra, E., Rebulla, P., et al. (2002) · PubMed · Cited by 178
Self-citationThe WHO classification of MDS does make a difference
Howe, R. B., Porwit‐MacDonald, A., Wanat, R., Tehranchi, R., & Hellström-Lindberg, E. (2003) · Blood · doi:10.1182/blood-2003-06-2124 · Cited by 147
Nösslinger, T., Reisner, R., Koller, E., Grüner, H., Tüchler, H., Nowotny, H., Pittermann, E., & Pfeilstöcker, M. (2001) · Blood · doi:10.1182/blood.v98.10.2935 · Cited by 119
Prognostic factors and scoring systems in myelodysplastic syndromes.
Sanz, G. F., Sanz, M. Á., & Greenberg, P. L. (1998) · PubMed · Cited by 102
Pfeilstöcker, M., Reisner, R., Nösslinger, T., Grüner, H., Nowotny, H., Tüchler, H., Schlögl, E., Pittermann, E., & Heinz, R. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01559.x · Cited by 83
Morel, P., Declercq, C., Hebbar, M., Bauters, F., & Fenaux, P. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.6122056.x · Cited by 52
FAB classification of myelodysplastic syndromes: merits and controversies
Verhoef, G. E. G., Pittaluga, S., Wolf‐Peeters, C. D., et al. (1995) · Annals of Hematology · doi:10.1007/bf01696227 · Cited by 37
Cited by
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 2,844
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Self-citationMalcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,032
Self-citation
Metadata
- Authors
- Malcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., Lazzarino, M., & Cazzola, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-20
- Volume
- 23
- Issue
- 30
- Pages
- 7594-7603
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149982846
- Cited by
- 865
- References
- 22
- FWCI
- 27.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.